Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 20/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 19/20 | 0.62 |
| ▸ | ALOX5 | P09917 | 11/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7139884 | 0.87 | PTGS2 (0.63) | PTGS2PTGS1ALOX5 | |
| SCHEMBL3582386 | 0.87 | PTGS2 (0.63) | PTGS2PTGS1ALOX5 | |
| SCHEMBL3584479 | 0.86 | PTGS2 (0.62) | PTGS2PTGS1ALOX5 | |
| SCHEMBL7795840 | 0.86 | PTGS2 (0.70) | PTGS2PTGS1ALOX5 | |
| SCHEMBL3592610 | 0.84 | PTGS2 (0.60) | PTGS2PTGS1ALOX5 | |
| SCHEMBL7161473 | 0.82 | PTGS2 (0.67) | PTGS2PTGS1ALOX5 | |
| SCHEMBL3580212 | 0.81 | PTGS2 (0.56) | PTGS2PTGS1ALOX5 | |
| SCHEMBL15726921 | 0.79 | PTGS2 (0.56) | PTGS2PTGS1ALOX5 | |
| SCHEMBL21028385 | 0.78 | PTGS2 (0.52) | PTGS2PTGS1ALOX5 | |
| SCHEMBL7141533 | 0.77 | PTGS2 (1.00) | PTGS2PTGS1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
| EP-1962605-A2 | 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007070433-A2 | 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007070433-A2 | 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CXCR2 | PTGS2 311/4885PTGS1 190/4885ALOX5 1015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.